PD-L1 Clinical Trials

4 recruiting

PD-L1 Trials at a Glance

11 actively recruiting trials for pd-l1 are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Beijing, Hangzhou, and Ankara. Lead sponsors running pd-l1 studies include Chang Gung Memorial Hospital, Institute of Oncology Ljubljana, and Antalya Training and Research Hospital.

Browse pd-l1 trials by phase

Treatments under study

About PD-L1 Clinical Trials

Looking for clinical trials for PD-L1? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PD-L1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PD-L1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled25 locationsNCT07279402
Recruiting

68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers

TumorPD-L1
The First Affiliated Hospital of Xiamen University100 enrolled1 locationNCT06754345
Recruiting
Phase 2

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery

Mucosal MelanomaPD-L1 Positive
The First Hospital of Jilin University220 enrolled1 locationNCT07400302
Recruiting

Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores

ImmunotherapyCirculating Tumor Cells (CTCs)PD-L1 Expression+1 more
Chang Gung Memorial Hospital150 enrolled1 locationNCT07396259
Recruiting
Phase 1Phase 2

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 3

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting
Phase 2

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc.2,000 enrolled3 locationsNCT06635954
Recruiting
Not Applicable

Biomarkers in Immunotherapy of Melanoma

Metastatic MelanomaImmune Checkpoints InhibitorsGastrointestinal Microbiome (Bacterial and Viral)+1 more
Institute of Oncology Ljubljana150 enrolled1 locationNCT05878977
Recruiting
Not Applicable

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

CancerPD-L1 Gene Mutation
Wuxi People's Hospital200 enrolled1 locationNCT06430502
Recruiting
Phase 2

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

PD-L1Locally Advanced Nasopharyngeal CarcinomaInduction Chemotherapy+1 more
Sun Yat-sen University36 enrolled1 locationNCT05397769